Enterome
Jérôme Kervevan has work experience spanning from 2015 to the present. Jérôme started their career as a Research Intern at CRCL - INSERM U1052 in January 2015, where they worked until June 2015. From February 2016 to December 2019, Jérôme served as a PhD student at IMRB - INSERM U955. Jérôme then joined Institut Pasteur in January 2020 as a Post-doctoral fellow, where they worked until October 2022. Currently, Jérôme is employed as a Scientist in immunology at Enterome since October 2022.
Jérôme Kervevan started their education in 2010 at the University of South Brittany, where they completed a Licence in Biologie-Environnement spécialité Biotechnologies in 2013. After that, they pursued further studies at Université de Rennes I from 2013 to 2015, earning a Master's degree in Sciences Cellulaires et Moléculaires du Vivant. Jérôme continued their academic journey at Université Paris-Est Créteil (UPEC) from 2016 to 2019, where they obtained a Doctor of Philosophy (PhD) degree in Immunology.
This person is not in any offices
Enterome
Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect oractions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.